Skip to content
Screener

Krystal Biotech, Inc. KRYS Net Change in Cash

Net Change in Cash at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$336.83M+60.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$49M-198%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$309.88M+321%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$11.36M-1,124%
Regenxbio logo
RegenxbioRGNX
$21.26M
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$49.73M+379%

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$9.64B+145%
Enterprise value$9.15B+155%
P/E42.9×+16.0×
P/S23.1×+12.2×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 7:06 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001711279-26-000043
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Taxes paid related to settlement of restricted stock awards(1,812)
Net cash (used in) financing activities(10,459)(12,466)
Effect of exchange rate changes on cash and cash equivalents(1,331)171
Net increase (decrease) in cash and cash equivalents5,009(36,095)
Cash and cash equivalents at beginning of period496,304344,865
Cash and cash equivalents at end of period$501,313$308,770
Supplemental Disclosures of Non-Cash Activities
Unpaid purchases of property and equipment$1,218$1,397

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Krystal Biotech, Inc.'s net change in cash?
Krystal Biotech, Inc. (KRYS) reported net change in cash of $5.01M in Q1 2026.
How has Krystal Biotech, Inc.'s net change in cash changed year-over-year?
Krystal Biotech, Inc.'s net change in cash increased by 113.9% year-over-year, from -$36.1M to $5.01M.
What is the long-term trend for Krystal Biotech, Inc.'s net change in cash?
Over 3 years (2022 to 2025), Krystal Biotech, Inc.'s net change in cash has grown at a -5.5% compound annual growth rate (CAGR), from -$179.35M to $151.44M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Krystal Biotech, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude